Electrophysiological, morphological, and ultrastructural features of the injured spinal cord tissue after transplantation of human umbilical cord blood mononuclear cells genetically modified with the VEGF and GDNF genes by Mukhamedshina Y. et al.
Neural Plasticity 2017 vol.2017
Electrophysiological, morphological, and ultrastructural
features of the injured spinal cord tissue after
transplantation of human umbilical cord blood
mononuclear cells genetically modified with the VEGF
and GDNF genes
Mukhamedshina Y., Gilazieva Z., Arkhipova S., Galieva L., Garanina E., Shulman A., Yafarova G.,
Chelyshev Y., Shamsutdinova N., Rizvanov A.
Kazan Federal University, 420008, Kremlevskaya 18, Kazan, Russia
Abstract
© 2017 Y. O. Mukhamedshina et al. In this study, we examined the efficacy of human umbilical
cord blood mononuclear cells (hUCB-MCs), genetically modified with the VEGF and GDNF genes
using adenoviral vectors, on posttraumatic regeneration after transplantation into the site of
spinal  cord  injury  (SCI)  in  rats.  Thirty  days  after  SCI,  followed  by  transplantation  of
nontransduced hUCB-MCs, we observed an improvement in H (latency period, LP) and M(Amax)
waves, compared to the group without therapy after SCI. For genetically modified hUCB-MCs,
there was improvement in Amax of M wave and LP of both the M and H waves. The ratio
between Amax of the H and M waves (Hmax/Mmax) demonstrated that transplantation into the
area of SCI of genetically modified hUCB-MCs was more effective than nontransduced hUCB-
MCs. Spared tissue and myelinated fibers were increased at day 30 after SCI and transplantation
of  hUCB-MCs  in  the  lateral  and  ventral  funiculi  2.5  mm  from  the  lesion  epicenter.
Transplantation of hUCB-MCs genetically modified with the VEGF and GNDF genes significantly
increased the number of spared myelinated fibers (22-fold, P > 0.01) in the main corticospinal
tract compared to the nontransduced ones. HNA + cells with the morphology of phagocytes and
microglia-like cells were found as compact clusters or cell bridges within the traumatic cavities
that were lined by GFAP + host astrocytes. Our results show that hUCB-MCs transplanted into
the site of SCI improved regeneration and that hUCB-MCs genetically modified with the VEGF
and GNDF genes were more effective than nontransduced hUCB-MCs.
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